Predicting immunotherapy response

Ben-Gurion University researchers have partnered Israel’s OncoHost to develop a biosensor that safely predicts if anti-PD1 therapy may cure a specific cancer patient. The leading immune checkpoint inhibitor (ICI) therapy is invasive and other treatments may be better. (see also here).

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *